Radiation sensitization of human cervical cancer by proteasome inhibitor Velcade (Bortezomib)

被引：0
|
作者：
Kamer, S.
Ren, Q.
Sui, Y. P.
Kari, C.
Rodeck, U.
Dicker, A. P.
机构：
[1] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2006.07.742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2334
引用
收藏
页码：S396 / S396
页数：1
相关论文
共 50 条
  • [31] Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects
    Shahshahan, Mohammad A.
    Beckley, Maureen N.
    Jazirehi, Ali R.
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2011, 1 (07): : 913 - 924
  • [32] Report of a phase II study of proteasome inhibitor Bortezomib (VELCADE™) in patients with relapsed or refractory indolent or aggressive lymphomas.
    Goy, A
    Hart, S
    Pro, B
    McLaughlin, P
    Younes, A
    Dang, N
    Fayad, L
    Romaguera, J
    Cabanillas, F
    Hagemeister, F
    Samaniego, F
    Wang, M
    Mesina, O
    Gilles, F
    Trehu, E
    Shenkein, D
    [J]. BLOOD, 2003, 102 (11) : 180A - 180A
  • [33] Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib)
    Chao, Ta-Hsiang
    Chauhan, Dharminder
    Deyanat-Yazdi, Gordafaried
    Catley, Laurence
    Richardson, Paul
    Lloyd, G. Kenneth
    Neuteboom, Saskia T. C.
    Anderson, Kenneth C.
    Palladino, Michael A.
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [34] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
  • [35] Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Mack, PC
    Davies, AM
    Lara, PN
    Gumerlock, PH
    Gandara, DR
    [J]. LUNG CANCER, 2003, 41 : S89 - S96
  • [36] Sensitization of human uterine cervical cancer cells to radiation using paclitaxel
    Suzuki, M
    Saga, Y
    Sekiguchi, I
    Sato, I
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1996, 57 (06): : 430 - 437
  • [37] The effect of proteasome inhibition with bortezomib(Velcade™) in B cell lymphoma cell lines
    Strauss, SJ
    Liu, W
    Maharaj, L
    Shringarpure, R
    Anderson, C
    Schenkein, D
    Lister, TA
    Joel, SP
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 : S65 - S65
  • [38] Proteasome inhibitor, bortezomib, for myeloma and lymphoma
    Tobinai, Kensei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 318 - 326
  • [39] The resistance mechanisms of proteasome inhibitor bortezomib
    Lü S.
    Wang J.
    [J]. Biomarker Research, 1 (1)
  • [40] Proteasome inhibitor, bortezomib, for myeloma and lymphoma
    Kensei Tobinai
    [J]. International Journal of Clinical Oncology, 2007, 12 : 318 - 326
12345